Antibacterial agent 81
Antibacterial agent 81 is a DNA transcription inhibitor. Antibacterial agent 81 inhibits S. aureus USA300 and M. smegmatis ATCC14468 with MIC values of 12.5 and 7.8 μM, respectively. Antibacterial agent 81 can be used for the research of infection.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 2873395-27-6
- Fòrmula: C33H28N2O8
- Peso molecular:580.58
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
In Vitro
Antibacterial agent 81 (20 μM; 15 min) inhibits DNA transcription with a 73% inhibition rate[1]. Antibacterial agent 81 (0-50 mM; 16-24 h) shows antibacterial activity towards S. aureus USA300, M. smegmatis ATCC14468, E. coli BW25113 and E. coli BW25113 ΔTolC with MIC values of 12.5, 7.8, ＞250, and ＞250 μM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
No. CAS 2873395-27-6
-
Peso molecular 580.58
-
Fòrmula C33H28N2O8
-
SMILES
COC1=CC=C(C=C1)C2=C(C3=C(C=C(C(C(C(NC4=CC=CC=C4C(O)=O)=O)=O)=C3N2)OC)OC)C5=CC=C(C=C5)OC
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Antibacterial agent 81 Related Classifications
HY-143292 Related Classifications
Powered by Bioz